Peptides: what physicians need to know
News, regulation and evidence on peptides in the Cayman Islands: what the law, the regulators and the studies say, with every fact linked to its source.
Regulation
Pharmacy Act 2024 still not in force in the Cayman Islands
Parliament passed a modern medicines law for the Cayman Islands in 2024. More than two years later it is still listed as not in force, so a 1979 law the Auditor General called out of line with good practice still governs medicine imports.
Read article →
Regulation
Cayman Health Practice Amendment 2026 lets Cabinet set standards
The Cayman Islands Parliament passed the Health Practice (Amendment) Bill, 2026, letting Cabinet impose binding standards on every registered practitioner, from prescribing to clinical research. A second amendment and a wider health law overhaul followed.
Read article →
Regulation
Clinical trials in the Cayman Islands: no phase 1, no paying patients
New Health Practice Commission standards set a high bar for clinical research in the Cayman Islands: phase 1 trials are ruled out, participants may not be charged, and significant events must be reported within 24 hours. What it means for peptide, stem cell and medical-tourism research.
Read article →
Regulation
Fake doctor charged in Cayman over controlled drug purchases
Police in the Cayman Islands charged a 66-year-old man with impersonating a doctor to buy prescription medication, including controlled drugs. The case tests the Health Practice Act's title offence and the islands' prescription controls.
Read article →
Evidence
Cayman obesity: STEPS data meets semaglutide and tirzepatide
Seven in ten adults in the Cayman Islands are overweight or obese, and the national STEPS survey found little change in a decade. Here is what the data show and what the GLP-1 evidence on semaglutide and tirzepatide adds for Caymanian physicians.
Read article →